Medical management of aortic disease in children with Marfan syndromeLindsay, Mark E.a,b,cCurrent Opinion in Pediatrics: October 2018 - Volume 30 - Issue 5 - p 639–644 doi: 10.1097/MOP.0000000000000671 CARDIOVASCULAR MEDICINE: Edited by Daniel Bernstein Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Marfan syndrome (MFS) is the most common cause of aortic aneurysm in children and is associated with premature mortality. Whereas surgical therapy remains the primary treatment to prevent aortic complications, medical therapy may slow or prevent aortic growth. Pediatricians and pediatric cardiologists should become familiar with the diagnosis and management of MFS. This review focuses on the medical management for the most important life-threatening manifestation of MFS, thoracic aortic disease. Recent findings Several large-scale clinical trials and one meta-analysis have been reported comparing angiotensin receptors blockers with the standard therapy, beta blockers. Summary From the assembled evidence described in this review, beta blockers and angiotensin receptors blockers show clinical equivalence and either class of agent may be an appropriate choice for the medical management of aortic growth in children with MFS. aMassachusetts General Hospital Thoracic Aortic Center bDivision of Cardiology cPediatric Cardiology, Departments of Medicine and Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence to Mark E. Lindsay, MD, PhD, Richard B. Simches Research Building, Room 3224, 185 Cambridge St., Boston, MA 02114, USA. Tel: +1 617 643 3458; fax: +1 617 643 3451; e-mail: Lindsay.Mark@mgh.harvard.edu Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.